Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down – Should You Sell?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) gapped down before the market opened on Monday . The stock had previously closed at $27.68, but opened at $26.19. Ascentage Pharma Group International shares last traded at $26.12, with a volume of 984 shares changing hands.

Analyst Ratings Changes

AAPG has been the topic of several recent analyst reports. Piper Sandler assumed coverage on Ascentage Pharma Group International in a report on Wednesday, November 5th. They set an “overweight” rating and a $48.00 target price on the stock. Lucid Cap Mkts raised Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, December 15th. Truist Financial set a $51.00 target price on shares of Ascentage Pharma Group International in a report on Monday, November 24th. BTIG Research assumed coverage on shares of Ascentage Pharma Group International in a research report on Monday, November 10th. They set a “buy” rating and a $50.00 price objective for the company. Finally, Oppenheimer initiated coverage on Ascentage Pharma Group International in a report on Thursday, December 4th. They set an “outperform” rating and a $45.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating and five have given a Buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $48.50.

Ascentage Pharma Group International Stock Down 6.8%

The company has a current ratio of 1.54, a quick ratio of 1.53 and a debt-to-equity ratio of 1.31. The firm has a 50-day moving average of $31.64 and a 200 day moving average of $36.77.

Institutional Investors Weigh In On Ascentage Pharma Group International

A number of institutional investors and hedge funds have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Ascentage Pharma Group International during the third quarter worth approximately $96,000. ABC Arbitrage SA acquired a new position in shares of Ascentage Pharma Group International in the third quarter valued at about $204,000. Chevy Chase Trust Holdings LLC bought a new position in Ascentage Pharma Group International during the second quarter worth about $227,000. Citadel Advisors LLC acquired a new position in shares of Ascentage Pharma Group International during the 3rd quarter worth approximately $383,000. Finally, Hsbc Holdings PLC bought a new position in shares of Ascentage Pharma Group International during the second quarter worth approximately $391,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.